Offering conducted to fund operations and general corporate purposes
By Devika Patel
Knoxville, Tenn., Aug. 29 - Rosetta Genomics Ltd. said the greenshoe was fully exercised in its $31.63 million public offering of stock. The deal was announced June 25 and priced for $27.5 million with a $4.13 million greenshoe on Aug. 2.
The company sold 6,325,000 ordinary shares at $5.00 per share, which is a 29.68% discount to the Aug. 1 closing share price of $7.11. Of the shares, 825,000 were part of the fully exercised greenshoe.
Aegis Capital Corp. was the bookrunner.
Proceeds will be used for operations and other general corporate purposes.
Based in Rehovot, Israel, Rosetta Genomics develops and provides microRNA-based molecular diagnostics.
| Issuer: | Rosetta Genomics Ltd.
|
| Issue: | Ordinary shares
|
| Amount: | $31,625,000 (including $4,125,000 greenshoe)
|
| Shares: | 6,325,000
|
| Price: | $5.00
|
| Warrants: | No
|
| Bookrunner: | Aegis Capital Corp.
|
| Announcement date: | June 25
|
| Pricing date: | Aug. 2
|
| Settlement date: | Aug. 29
|
| Stock symbol: | Nasdaq: ROSG
|
| Stock price: | $7.11 at close Aug. 1
|
| Market capitalization: | $4.28 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
